Emerging Strategies in the Diagnosis and Treatment of Pleural Mesothelioma: An Overview
Thoracic Cancer · 2026-04 · 17 (8)
DOI: 10.1111/1759-7714.70259 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Thoracic Cancer, online erschienen am 23.04.2026. Verfasst von Raffaella Pagliaro und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy. Hauptthemen laut MEDLINE: Pleural Neoplasms, Mesothelioma, Mesothelioma, Malignant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pleural mesothelioma (PM) is a rare and aggressive cancer arising from pleural mesothelial cells with a strong association to asbestos exposure. Among the diagnostic strategies available are noninvasive techniques including thoracic ultrasound (TUS), computed tomography (CT) scans, positron emission tomography (PET‐CT), and invasive procedures such as thoracoscopy and pleural biopsy. Accurate identification of the histological subtype is critical for tailoring treatment strategies. The standard treatment for unresectable PM has traditionally been chemotherapy, particularly platinum and pemetrexed. However, recent advances in translational clinical research, including immune checkpoint inhibitors (ICIs), are changing the therapeutic landscape, offering new opportunities for personalized treatment. The recent FDA approval of nivolumab and ipilimumab combination therapy as a first‐line treatment has significantly improved outcomes, especially for nonepithelioid subtypes. Ongoing studies are exploring additional immune‐targeted therapies such as VISTA, LAG‐3, and dendritic cell‐based therapies. Early detection, refined biomarker identification, and a deeper understanding of the tumor microenvironment remain essential to improving PM prognosis and patient survival. This review provides a comprehensive exploration of the epidemiology, etiology, clinical manifestations, diagnostic approaches (including immunohistochemical and molecular markers), staging, and current treatment strategies for PM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy.
- Unit of Respiratory Medicine "Luigi Vanvitelli", A.O. Dei Colli, Monaldi Hospital, Naples, Italy.
- Department of Thoracic Surgery, Policlinico Vanvitelli-University of Campania, Naples, Italy.
- Division of Radiology, Istituto Nazionale Tumori IRCCS Fondazione Pascale-IRCCS di Napoli., Napoli, Italy.
- Department of Medicine and Health Science, Vincenzo Tiberio University of Molise, Campobasso, Italy.
- Lega Italiana Per la Lotta Contro i Tumori, Rome, Italy.
ORCID-Profile: Raffaella Pagliaro, Beatrice Leonardi, Carmine Picone, Alfonso Fiorelli
Zitieren
APA
Pagliaro, R., Leonardi, B., Schiattarella, A., Bergameo, G., Picone, C., D'Errico, A. G., Scialò, F., Perrotta, F., De Rimini, M. L., Fiorelli, A., & Bianco, A. (2026). Emerging Strategies in the Diagnosis and Treatment of Pleural Mesothelioma: An Overview. Thoracic Cancer, 17(8). https://doi.org/10.1111/1759-7714.70259
Vancouver
Pagliaro R, Leonardi B, Schiattarella A, Bergameo G, Picone C, D'Errico AG, et al. Emerging Strategies in the Diagnosis and Treatment of Pleural Mesothelioma: An Overview. Thoracic Cancer. 2026;17(8). doi:10.1111/1759-7714.70259
BibTeX
@article{Pagliaro2026,
author = {Pagliaro, Raffaella and Leonardi, Beatrice and Schiattarella, Angela and Bergameo, Grazia and Picone, Carmine and D'Errico, Adolfo Gallipoli and Scialò, Filippo and Perrotta, Fabio and De Rimini, Maria Luisa and Fiorelli, Alfonso and Bianco, Andrea},
title = {Emerging Strategies in the Diagnosis and Treatment of Pleural Mesothelioma: An Overview},
journal = {Thoracic Cancer},
year = {2026},
volume = {17},
number = {8},
doi = {10.1111/1759-7714.70259}
}
EUVIMED